Trial
NCT04267939
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
GlaxoSmithKline
Condition
Advanced Solid Tumors (Excluding Prostate Cancer)
Intervention
Elimusertib (BAY1895344)
Why stopped
There was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore Sponsor has decided to terminate the investigation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-21